Vivos Therapeutics

Vivos Therapeutics, Inc. is a medical technology company which engages in the development and commercialization of treatment alternatives for patients with sleep disordered breathing (SDB). Its solutions are also offered for patients with mild-to-moderate obstructive sleep apnea (OSA). The company was founded by Gurdev Dave Singh, Susan McCullough, RaeAnn Byrnes, Todd Huntsman, and R. Kirk Huntsman on July 7, 2016 and is headquartered in Highlands Ranch, CO.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q3 2022

Earnings data Q2 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Vivos Therapeutics reports revenue decline but eyes growth through FDA clearances

Vivos Therapeutics reported a decline in revenue for Q1 2024 but showcased improved operating performance and cash flow management. The company is focused on revenue growth initiatives, strategic collaborations, and expanding product access to achieve cash flow positivity by late 2024 or early 2025. Challenges include revenue decline and the need to reduce dependency on dentistry channel.

Vivos Therapeutics reports robust Q2 earnings, eyes market expansion

Vivos Therapeutics delivered a strong Q2 2024 performance with revenue growth, improved margins, and cost management driving financial stability and operational efficiency.
The company's strategic initiatives, including the alliance with a sleep clinic and FDA clearances, position it well for market expansion and revenue enhancement.
While challenges in maintaining growth and managing costs persist, Vivos has opportunities to leverage its strengths in customer loyalty, financial stability, and market reach for sustainable growth.
By focusing on revenue optimization, cost control, and strategic partnerships, Vivos aims to enhance profitability, drive innovation, and capture new market opportunities.

Vivos Therapeutics reports revenue growth and strategic expansion plans

Vivos Therapeutics showed revenue growth and improved gross profit margins in Q3 2024. Despite challenges in net loss and cash burn, the company is optimistic about achieving positive cash flow and expanding its market presence through strategic alliances.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Vivos Therapeutics, Inc. is a medical technology company which engages in the development and commercialization of treatment alternatives for patients with sleep disordered breathing (SDB). Its solutions are also offered for patients with mild-to-moderate obstructive sleep apnea (OSA). The company was founded by Gurdev Dave Singh, Susan McCullough, RaeAnn Byrnes, Todd Huntsman, and R. Kirk Huntsman on July 7, 2016 and is headquartered in Littleton, CO.

Vivos Therapeutics Inc (NASDAQ:VVOS) has reported a rise in revenue to $3.9 million for its first quarter ended March 31, 2023, up from $3.6 million in the same period last year. The company said the increase in revenue was attributed to higher Vivos Integrated Provider (VIP) enrollments and increased revenue from seminars conducted at the Vivos Institute.

Vivos Therapeutics reports rise in first quarter revenue

Vivos Therapeutics, Inc. (VVOS) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to loss of $0.26 per share a year ago.

Vivos Therapeutics, Inc. (VVOS) Reports Q1 Loss, Tops Revenue Estimates

Revenue increased 6% Year-Over-Year; Operating Expenses Decreased 20%  as Cost Cutting Initiatives Take Hold

Vivos Therapeutics Reports First Quarter 2023 Financial Results and Provides Operational Update

LITTLETON, Colo., June 06, 2023 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company'') (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment methods for patients suffering from a variety of health conditions, many of which are associated with breathing related sleep issues arising from certain dentofacial abnormalities, today announced it plans to release its first quarter 2023 financial results after market close on Thursday, June 8, 2023.

Vivos Therapeutics Schedules Release of First Quarter 2023 Financial Results and Conference Call

Vivos Therapeutics (NASDAQ:VVOS) Inc announced what it calls “a broad set of initiatives” designed to improve operational efficiencies, reduce expenses, and position the company to take advantage of growth opportunities. “Vivos has made major strides in recovering from challenges imposed by the COVID-19 pandemic on the dental industry which lost tens of thousands of qualified dental practice personnel, including many who were trained in the Vivos Method,” CEO Kirk Huntsman said in a statement.

Vivos Therapeutics expects to reach positive cash flow a full quarter earlier thanks to new initiatives

Vivos Therapeutics (NASDAQ:VVOS) said its recently acquired Preventive Oral Device, known as POD, has been shown to treat and prevent headaches in a clinical observational study, sending the company's shares skyrocketing.  The US Food and Drug Administration (FDA) 510k-cleared device is worn during sleep to treat Temporomandibular Joint Dysfunction and its symptoms such as headaches and face or neck pain.

Vivos Therapeutics reports positive results from migraine study; shares skyrocket

Study Data Highlights New Vivos Treatment Option is Highly Effective in Treating Migraine Headaches, One of the World's Most Common Illnesses Study Data Highlights New Vivos Treatment Option is Highly Effective in Treating Migraine Headaches, One of the World's Most Common Illnesses

Clinical Study Shows 92% of Patients Report Resolution of Migraine Headaches Using Vivos' POD® Appliance Treatment

Vivos Therapeutics, Inc. (NASDAQ:VVOS ) Q4 2022 Results Conference Call March 30, 2023 5:00 PM ET Company Participants Julie Gannon - Investor Relations Officer Kirk Huntsman - Chairman and Chief Executive Officer Brad Amman - Chief Financial Officer Conference Call Participants Scott Henry - ROTH Capital Partners Lucas Ward - Ascendiant Capital Markets Operator Good day, everyone, and welcome to the Vivos Therapeutics Fourth Quarter and Full Year 2022 Earnings Conference Call. At this time participants are in a listen-only mode.

Vivos Therapeutics, Inc. (VVOS) Q4 2022 Earnings Call Transcript

Vivos Therapeutics (NASDAQ:VVOS), Inc has announced its fiscal 2022 financial results and provided an operational update, saying it believes its 2022 and early 2023 accomplishments, including the completion of a capital raise for net proceeds of about $7.4 million, cost reductions and a new technology acquisition, have set the stage for potential 2023 revenue growth. The medical device and technology company recorded revenue of $16 million for the full year ended December 31, 2022, which excludes about $2.5 million of Vivos Integrated Provider (VIP) enrollment revenue that is expected to be recognized during the next 17 months.

Vivos Therapeutics says 2022 and early 2023 accomplishments sets stage for potential revenue growth this year

2022 and Early 2023 Accomplishments, Including Capital Raise, Cost Reductions and New Technology Acquisition, Set the Stage for Potential 2023 Revenue Growth

Vivos Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Operational Update

Call Scheduled for Today, Thursday, March 30, 2023 at 5:00 pm ET Call Scheduled for Today, Thursday, March 30, 2023 at 5:00 pm ET

Vivos Therapeutics Schedules Release of Fourth Quarter and Full Year 2022 Financial Results and Conference Call

LITTLETON, Colo., March 08, 2023 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (the “Company” or “Vivos”) (NASDAQ:VVOS), a medical device and technology company that delivers training and a full line of highly effective proprietary oral appliances for the treatment of breathing related sleep disorders in adults, including mild-to-moderate obstructive sleep apnea (OSA) and snoring, today announced that Kirk Huntsman, Vivos' Chairman and CEO and Brad Amman, CFO, will participate in a fireside chat at the 35th Annual ROTH Conference on Tuesday, March 14, 2023 at 1:30 pm PT (4:30 pm ET).

Vivos Therapeutics to Participate in Fireside Chat at the 35th Annual ROTH Conference

The stock price of Vivos Therapeutics Inc (NASDAQ: VVOS) fell by 27.87% in the most recent trading session. This is why.

VVOS Stock: 27.87% Decrease Exaplanation

Acquisition Adds Complementary, Lower Cost Products for Treating Conditions Associated with Obstructive Sleep Apnea Acquisition Adds Complementary, Lower Cost Products for Treating Conditions Associated with Obstructive Sleep Apnea

Vivos Therapeutics Expands Product Line and Revenue Potential with Acquisition of Product Rights and Patents from Advanced Facialdontics, LLC

Chairman and CEO Kirk Huntsman to Present at 12:35 pm ET Chairman and CEO Kirk Huntsman to Present at 12:35 pm ET

Vivos Therapeutics to Present at the Emerging Growth Conference on February 22, 2023

LITTLETON, Colo., Jan. 20, 2023 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company'') (NASDAQ: VVOS), a medical technology company focused on developing innovative treatments for patients suffering from dentofacial abnormalities and/or mild-to-moderate obstructive sleep apnea (OSA) and snoring in adults, today announced that it has received a notice from the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) informing Vivos it has regained compliance with the minimum bid price requirement for continued listing on the Nasdaq under Nasdaq Listing Rule 5550(a)(2).

Vivos Therapeutics Regains Compliance with Nasdaq Listing Requirements

New capital extends cash runway as Vivos seeks to drive revenue growth and manage expenses in 2023 New capital extends cash runway as Vivos seeks to drive revenue growth and manage expenses in 2023

Vivos Therapeutics Closes $8 Million Private Placement

LITTLETON, Colo., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company'') (NASDAQ: VVOS), a medical technology company focused on developing innovative treatments for patients suffering from dentofacial abnormalities and/or mild-to-moderate obstructive sleep apnea (OSA) and snoring in adults, today announced that it has entered into a definitive agreement with a single institutional investor to raise approximately $8 million in a private placement offering at a price of $1.20 per unit. Each unit consists of one share of common stock (or a pre-funded warrant to purchase one share of common stock) and one warrant exercisable for one share common stock at a price of $1.20 per share for a period of five years and 6 months from closing. No actual units will be issued in the offering.

Vivos Therapeutics Announces Pricing of $8 Million Private Placement

Geron

SoFi Technologies

Here's why penny stocks climb in price The post What Makes Penny Stocks Move? 3 Major Factors to Consider appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

What Makes Penny Stocks Move? 3 Major Factors to Consider

Vivos Therapeutics (NASDAQ: VVOS ) stock is rocketing higher on Wednesday as investors react to positive news from the U.S. Food and Drug Administration (FDA). The FDA has approved Vivos Therapeutics' proprietary DNA appliance.

The Sleep Apnea News That Has VVOS Stock Soaring Today

Approval represents third FDA clearance for Vivos' oral appliances and first clearance specifically recognizing Vivos' proprietary core technology Approval represents third FDA clearance for Vivos' oral appliances and first clearance specifically recognizing Vivos' proprietary core technology

Vivos Therapeutics Receives FDA 510(k) Clearance of its Flagship DNA Oral Appliance for Treatment of Obstructive Sleep Apnea

Vivos Therapeutics, Inc. (NASDAQ:VVOS ) Q2 and Q3 2022 Earnings Conference Call December 20, 2022 5:00 PM ET Company Participants Julie Gannon - Chief of Staff and Investor Relations Kirk Huntsman - Chairman and Chief Executive Officer Brad Amman - Chief Financial Officer Conference Call Participants Scott Henry - ROTH Capital Alexander Nowak - Craig-Hallum Capital Group Operator Good day, everyone and welcome to the Vivos Therapeutics Second and Third Quarter 2022 Earnings Conference Call. At this time participants are in a listen-only mode.

Vivos Therapeutics, Inc. (VVOS) Q2 and Q3 2022 Earnings Call Transcript

Second and Third Quarter 10-Q Filings Bring Vivos Current on SEC Filings for Nasdaq Stock Market Purposes

Vivos Therapeutics Reports Second and Third Quarter 2022 Financial Results and Provides Operational Update

Call Scheduled for Tuesday, December 20, 2022 at 5:00 pm ET Call Scheduled for Tuesday, December 20, 2022 at 5:00 pm ET

Vivos Therapeutics Schedules Release of Second and Third Quarter 2022 Financial Results and Conference Call

New Collaboration to Increase Payer Reimbursements and Patient Access New Collaboration to Increase Payer Reimbursements and Patient Access

News for Vivos Therapeutics Stock (VVOS)